Group One Trading
RXRX icon

Group One Trading’s Recursion Pharmaceuticals RXRX Stock Holding History

Group One Trading’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Sell
783,035
-118,076
-13% -$393K ﹤0.01% 1876
2026
Q1 		$2.77M Buy
+901,111
New +$3.48M 0.01% 1782
2025
Q4 		– Sell
-238,590
Closed -$1.18M – 9023
2025
Q3 		$1.16M Buy
238,590
+151,737
+175% +$797K ﹤0.01% 2870
2025
Q2 		$439K Sell
86,853
-272,613
-76% -$1.34M ﹤0.01% 3552
2025
Q1 		$1.9M Buy
359,466
+77,762
+28% +$567K 0.01% 1857
2024
Q4 		$1.9M Buy
281,704
+91,529
+48% +$615K ﹤0.01% 1963
2024
Q3 		$1.25M Buy
190,175
+65,334
+52% +$468K ﹤0.01% 2112
2024
Q2 		$936K Buy
+124,841
New +$1.09M ﹤0.01% 2039
2023
Q4 		– Sell
-6,229
Closed -$44.4K – 8092
2023
Q3 		$47.7K Buy
+6,229
New +$62.1K ﹤0.01% 5139
2023
Q1 		– Sell
-5,471
Closed -$43.4K – 7858
2022
Q4 		$42.2K Sell
5,471
-1,429
-21% -$14K ﹤0.01% 5124
2022
Q3 		$73K Buy
+6,900
New +$69.9K ﹤0.01% 5076

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Group One Trading's RXRX Position: Q2 2026 in Review

Group One Trading reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, selling an estimated $393K and leaving 783,035 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Group One Trading first reported a position in RXRX in Q3 2022 and has held it in 11 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Group One Trading held 783,035 shares of Recursion Pharmaceuticals worth $2.87M as of Q2 2026.
  • Group One Trading sold 118,076 Recursion Pharmaceuticals shares in Q2 2026, an estimated $393K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #1876 holding.
  • Group One Trading first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.